natgillin/translations-raw huggingface dataset:
Only use TRAVATAN for dropping in your or your child’s eye(s).
Zdravilo TRAVATAN uporabljajte le za vkapanje v svoje oko(oči) ali v oko(oči) vašega otroka.
Only use TRAVATAN in both eyes if your doctor told you to.
Zdravilo TRAVATAN smete uporabljati na obeh očeh le, če tako predpiše zdravnik.
Only use your pen for up to 4 weeks after its first use.
Peresnik uporabljajte le do 4 tedne potem, ko ste ga prvič uporabili.
Only vaccinate healthy animals.
Cepite samo zdrave živali.
Only vaccinate healthy birds.
Cepite samo zdrave ptice.
Only very limited data are available from repeat-dose toxicity studies with respect to the risk for adverse effects on the male reproductive system.
Na voljo so zelo omejeni podatki iz študij toksičnosti ponavljajočih se odmerkov, glede na tveganje za neželene učinke na moški reproduktivni sistem.
Only wear one Exelon patch at a time and replace the patch with a new one after 24 hours.
Nosite samo en transdermalni obliž Exelon naenkrat in ga po 24 urah zamenjajte z novim.
Only wear one Exelon patch at a time and replace the patch with a new one after 24 hours.
Nosite samo en transdermalni obliž naenkrat in ga po 24 urah zamenjajte z novim.
Only wear one patch at a time.
Nosite samo en obliž naenkrat.
Only wear one Prometax patch at a time and replace the patch with a new one after 24 hours.
Nosite samo en transdermalni obliž naenkrat in ga po 24 urah zamenjajte z novim.
Only wear one Prometax patch at a time and replace the patch with a new one after 24 hours.
Nosite samo en transdermalni obliž Prometax naenkrat in ga po 24 urah zamenjajte z novim.
Only wear one Rivastigmine 3M Health Care Ltd. patch at a time and replace the patch with a new one after 24 hours.
Nosite samo en transdermalni obliž Rivastigmin 3M Health Care Ltd. naenkrat in ga po 24 urah zamenjajte z novim.
Only when used in combination with dabrafenib
amo pri uporabi v kombinaciji z dabrafenibom
Only your physician can administer Humalog by the intravenous route.
Samo vaš zdravnik vam lahko da zdravilo Humalog intravensko.
Only your physician can administer Liprolog by the intravenous route.
Samo vaš zdravnik vam lahko da zdravilo Liprolog intravensko.
Onsenal 200 mg capsules Celecoxib
Onsenal 200 mg kapsule celekoksib
Onsenal 200 mg hard capsules
Onsenal 200 mg trde kapsule
Onsenal 400 mg capsules Celecoxib
Onsenal 400 mg kapsule celekoksib
Onsenal 400 mg hard capsules
Onsenal 400 mg trde kapsule
Onsenal also reduced the number of polyps in patients aged 10 to 14 years with FAP.
Zdravilo Onsenal je povzročilo tudi zmanjšanje števila polipov pri bolnikih, starih od 10 do 14 let, ki so imeli familiarno adenomatozno polipozo.
Onsenal celecoxib
Onsenal celekoksib
Onsenal contains lactose (a type of sugar).
Zdravilo Onsenal vsebuje laktozo (vrsto sladkorja).
Onsenal has been authorised under ‘exceptional circumstances’.
Zdravilo Onsenal je bilo odobreno v „izjemnih okoliščinah“.
Onsenal is indicated for the reduction of the number of adenomatous intestinal polyps in familial adenomatous polyposis (FAP), as an adjunct to surgery and further endoscopic surveillance (see section 4.4).
Onsenal je indiciran za zmanjšanje števila adenomatoznih intestinalnih polipov pri familiarni adenomatozni polipozi (FAP) kot dodatek operaciji in nadaljnjemu endoskopskemu nadzoru (glejte poglavje 4.4).
Onsenal is used in addition to surgery (to remove the polyps) and endoscopic monitoring (to check if polyps are developing, using an endoscope, a thin tube that allows a doctor to look inside the gut).
Zdravilo Onsenal se uporablja kot dodatek operaciji (za odstranitev polipov) in endoskopskemu nadzoru (preverjanju, ali nastajajo polipi, kar se opravi z endoskopom – tanko cevko, s katero zdravnik lahko opazuje notranjost črevesja).
Onsenal should be used along with the usual care for FAP patients such as surgery and endoscopic surveillance.
Zdravilo Onsenal je treba pri bolnikih s FAP uporabljati hkrati z običajno zdravstveno oskrbo, npr. operacijami in endoskopskim nadzorom.
Onset of Action
Začetek delovanja
Onset of action is within ½ hour, reaches a maximum effect within 1.5–3.5 hours and the entire duration of action is approximately 7–8 hours.
Delovati začne v ½ ure, največji učinek doseže v 1,5–3,5 urah, celotni čas delovanja pa je približno 7– 8 ur.
Onset of action is within ½ hour, reaches a maximum effect within 2–8 hours and the entire duration of action is up to 24 hours.
Delovati začne v 1/2 ure, največji učinek doseže v 2–8 urah, celotni čas delovanja pa je do 24 ur.
Onset of hypophosphatasia was under 6 months in 4 patients, between 6 months and 18 years in 12 patients and over 18 years in 2 patients.
Pri 4 bolnikih je hipofosfatazija nastopila pri manj kot 6 mesecih, pri 12 bolnikih je nastopila med 6 meseci in 18 leti in pri 2 bolnikih pri več kot 18 letih.
Onset of hypophosphatasia was under 6 months in all patients.
Pri vseh bolnikih je hipofosfatazija nastopila pri manj kot 6 mesecih.
Onset of immunity against Marek’s disease: 1 week of age.
Nastop imunosti proti Marekovi bolezni: 1 teden starosti.
Onset of immunity against Newcastle disease: 3 weeks of age.
Nastop imunosti proti Newcastle bolezni: 3 teden starosti.
Onset of immunity has been demonstrated 4 weeks after vaccination.
Nastop imunosti je bil dokazan 4 tedne po cepljenju.
Onset of immunity: 14 days
Nastop imunosti: 14 dni.
Onset of immunity: 14 days
Razvoj imunosti: 14 dni.
Onset of immunity: 15 days after completion of the primary vaccination course.
Začetek imunosti: 15 dni po osnovnem programu cepljenja.
Onset of immunity: 15 days after completion of the primary vaccination scheme.
Začetek imunosti: 15 dni po osnovnem programu cepljenja.
Onset of immunity: 2 weeks after basic vaccination.
Začetek imunosti: 2 tedna po osnovnem cepljenju
Onset of immunity: 2 weeks after primary vaccination course of two injections.
Začetek imunosti: 2 tedna po osnovnem cepljenju (2 injekciji)
Onset of immunity: 2 weeks after primary vaccination course.
Nastop imunosti: dva tedna po prvem cepljenju.
Onset of immunity: 2 weeks after the primary vaccination course Duration of immunity: 17 months after the primary vaccination course
Razvoj imunosti: 2 tedna po osnovnem cepljenju Trajanje imunosti: 17 mesecev po osnovnem cepljenju
Onset of immunity: 2 weeks after the primary vaccination course Duration of immunity: 5 months after the primary vaccination course
Razvoj imunosti: 2 tedna po osnovnem cepljenju Trajanje imunosti: 5 mesecev po osnovnem cepljenju
Onset of immunity: 2 weeks after vaccination.
Začetek imunosti: 2 tedna po cepljenju
Onset of immunity: 2 weeks Duration of immunity: 22 weeks.
Začetek imunosti: 2 tedna Trajanje imunosti: 22 tednov
Onset of immunity: 2 weeks.
Nastop imunosti: 2 tedna.
Onset of immunity: 21 days after vaccination Duration of immunity: 105 days after vaccination
Razvoj imunosti: 21 dni po cepljenju Trajanje imunosti: 105 dni po cepljenju
Onset of immunity: 28 days after vaccination.
Začetek imunosti: 28 dni po cepljenju.
Onset of immunity: 3 weeks after completion of the primary course.
Razvoj imunosti: 3 tedne po zaključku osnovnega cepljenja.
Onset of immunity: 3 weeks after the primary vaccination for the panleucopenia and leukaemia components, and 4 weeks after the primary vaccination for the calicivirus and rhinotracheitis virus components.
Začetek imunosti: 3 tedne po prvem cepljenju za sestavine za panlevkopenijo in levkemijo in 4 tedne po prvem cepljenju za sestavine kalicivirusa in virusnega rinotraheitisa.
Onset of immunity: 3 weeks after the primary vaccination for the panleucopenia and leukaemia components, and 4 weeks after the primary vaccination for the calicivirus and rhinotracheitis virus components.
Začetek imunosti: 3 tedne po prvem cepljenju za sestavine za panlevkopenijo in levkemijo in 4 tedne po prvem cepljenju za sestavine za kalicivirus in virusni rinotraheitis.
Onset of immunity: 3 weeks after the primary vaccination.
Začetek imunosti: 3 tedne po prvem cepljenju.
Onset of immunity: 3 weeks Duration of immunity: 1 year
Začetek imunosti: 3 tedne Trajanje imunosti: 1 leto
Onset of immunity: 31 days after the second dose.
Začetek imunosti: 31 dni po drugem odmerku.
Onset of immunity: 4 weeks after the completion of primary course.
Razvoj imunosti: 4 tedne po zaključku osnovnega cepljenja.
Onset of immunity: 7 days
Nastop imunosti: 7 dni
Onset of immunity: 7 days after primary vaccination
Nastop imunosti: 7 dni po primarnem cepljenju
Onset of immunity: from 3 weeks after vaccination.
Začetek imunosti: od 3. tedna po cepljenju.
Onset of immunity: from 3 weeks post-vaccination.
Začetek imunosti: od 3. tedna po cepljenju.
Onset of immunity: Three weeks after the basic vaccination course.
Razvoj imunosti: tri tedne po osnovnem cepljenju.
Onset of protection against PCV2 occurs from as early as two weeks after the injection and lasts for at least 17 weeks.
Zaščita proti PCV2 nastopi že drugi teden po injiciranju in traja najmanj 17 tednov.
Onset of protection: 2 weeks post vaccination Duration of protection: at least 17 weeks.
Začetek zaščite: 2 tedna po cepljenju Trajanje zaščite: najmanj 17 tednov
Onset of protection: 2 weeks post vaccination Duration of protection: at least 17 weeks.
Začetek zaščite:: 2 tedna po cepljenju Trajanje zaščite: najmanj 17 tednov
onset or worsening of diabetes, ketoacidosis (ketones in the blood and urine) or coma,
pojav sladkorne bolezni (diabetesa) ali njeno poslabšanje, ketoacidoza (ketoni v krvi in urinu) ali koma,
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis and calicivirus components.
Imunost proti kužnemu rinotraheitisu in kalicivirozi mačk nastopi 1 teden po osnovnem cepljenju.
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and Chlamydophila felis components.
Imunost proti kužnemu rinotraheitisu,kalicivirozi mačk in Chlamydophila felis nastopi 1 teden po osnovnem cepljenju.
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus, Chlamydophila felis and panleucopenia components.
Imunost proti kužnemu rinotraheitisu, kalicivirozi mačk, okužbam s Chlamydophila felis in panleukopeniji mačk nastopi 1 teden po osnovnem cepljenju.
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus, Chlamydophila felis and panleucopenia components.
Imunost proti kužnemu rinotraheitisu,kalicivirusu mačk, okužbam s Chlamydophila felis in panleukopeniji mačk nastopi 1teden po osnovnem cepljenju.
Onsets of immunity have been demonstrated 1 week after primary vaccination course for the rhinotracheitis, calicivirus and panleucopenia components.
Imunost proti kužnemu rinotraheitisu, kalicivirozi mačk in mačji panleukopeniji nastopi 1 teden po osnovnem cepljenju.
Onsets of immunity have been demonstrated 1week after primary vaccination course for rhinotracheitis and calicivirus components.
Imunost proti kužnemu rinotraheitisu in kalicivirusu mačk nastopi 1 teden po osnovnem cepljenju.
Onsior 20 mg/ml solution for injection for cats and dogs
Onsior 20 mg/ml raztopina za injiciranje za mačke in pse
Onsior 20 mg/ml solution for injection for cats and dogs Robenacoxib
Onsior 20 mg/ml raztopina za injiciranje za mačke in pse Robenakoksib
Onsior 5 mg tablets for dogs: EU/2/08/089/004 (7 tablets) EU/2/08/089/005 (14 tablets)
Onsior 5 mg tablete za pse: EU/2/08/089/004 (7 tablet) EU/2/08/089/005 (14 tablet)
Onsior contains robenacoxib which belongs to a class of medicines that reduce fever, pain and inflammation.
Zdravilo Onsior vsebuje robenakoksib, ki spada v skupino zdravil, ki zmanjšujejo povišano telesno temperaturo, bolečino in vnetje.
Onsior has been studied in laboratory animals, as well as ‘clinical studies’ in cats and dogs that were treated in veterinary practices and clinics across Europe and in the USA.
Zdravilo Onsior so proučevali na laboratorijskih živalih ter v „kliničnih študijah“ na mačkah in psih, ki so bili zdravljeni v veterinarskih ambulantah in klinikah po Evropi in ZDA.
Onsior must not be administered in conjunction with other NSAIDs.
Onsior se ne sme uporabljati skupaj z drugimi NSAID.
Onsior robenacoxib
Onsior robenakoksib
Onsior solution for injection for cats and dogs is available in a cardboard box containing 1 vial with 20 ml solution for injection.
Onsior raztopina za injiciranje za mačke in pse je na voljo v kartonski škatli, ki vsebuje 1 vialo z 20 ml raztopine za injiciranje.
Onsior tablets are easy to administer and well accepted by most cats.
Onsior tablete so enostavne za uporabo in jih večina mačk dobro sprejme.
Onsior tablets are flavoured and are taken voluntarily by most dogs.
Onsior tablete so aromatizirane in jih večina psov sprejme prostovoljno.
Onsior tablets are flavoured and are taken voluntarily by most dogs.
Onsior tablete so aromatizirane in jih večino psov sprejme prostovoljno.
Onsior tablets for cats are available in cardboard boxes containing 1, 2, 5 or 10 blisters.
Onsior tablete za mačke so na voljo v kartonskih škatlah, ki vsebujejo 1, 2, 5 ali 10 pretisnih omotov.
Onsior tablets for dogs are available in cardboard boxes containing 1, 2, 4 or 10 blisters.
Onsior tablete za pse so na voljo v kartonskih škatlah, ki vsebujejo 1, 2, 4 ali 10 pretisnih omotov.
ONTARGET (ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) compared the effects of telmisartan, ramipril and the combination of telmisartan and ramipril on cardiovascular outcomes in 25620 patients aged 55 years or older with a history of coronary artery disease, stroke, TIA, peripheral arterial disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage (e.g. retinopathy, left ventricular hypertrophy, macro- or microalbuminuria), which is a population at risk for cardiovascular events.
Preskušanje ONTARGET (ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) je primerjalo učinke telmisartana, ramiprila in kombinacije telmisartana in ramiprila na srčnožilne izide pri 25620 bolnikih, starih 55 let ali več z anamnezo bolezni koronarnih arterij, možganske kapi, TIA, bolezni perifernih arterij ali sladkorno boleznijo tipa 2 in znaki okvare končnih organov (npr. retinopatijo, hipertrofijo levega prekata, makro- in mikroalbuminurijo), kar je populacija s tveganjem srčnožilne dogodkov.
ONTARGET (ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) compared the effects of telmisartan, ramipril and the combination of telmisartan and ramipril on cardiovascular outcomes in 25620 patients aged 55 years or older with a history of coronary artery disease, stroke, TIA, peripheral arterial disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage (e.g. retinopathy, left ventricular hypertrophy, macro- or microalbuminuria), which is a population at risk for cardiovascular events.
Preskušanje ONTARGET (ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) je primerjalo učinke telmisartana, ramiprila in kombinacije telmisartana in ramiprila na srčnožilne izide pri 25620 bolnikih, starih 55 let ali več z anamnezo bolezni koronarnih arterij, možganske kapi, TIA, bolezni perifernih arterij ali sladkorno boleznijo tipa 2 in znaki okvare končnih organov (npr. retinopatijo, hipertrofijo levega prekata, makro- in mikroalbuminurijo), kar je populacija s tveganjem srčnožilnih dogodkov.
ONTARGET (ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) compared the effects of telmisartan, ramipril and the combination of telmisartan and ramipril on cardiovascular outcomes in 25620 patients aged 55 years or older with a history of coronary artery disease, stroke, TIA, peripheral arterial disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage (e.g. retinopathy, left ventricular hypertrophy, macro- or microalbuminuria), which is a population at risk for cardiovascular events.
V študiji ONTARGET (ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) so primerjali učinke telmisartana, ramiprila in kombinacije telmisartana in ramiprila na srčnožilne izide pri 25.620 bolnikih, starih 55 let ali starejših, ki so imeli v anamnezi koronarno arterijsko bolezen, možgansko kap, TIA, periferno žilno bolezen ali sladkorno bolezen tipa 2 hkrati s potrjeno okvaro tarčnih organov (npr. retinopatijo, hipertrofijo levega prekata, makro- ali mikroalbuminurijo) in predstavljajo širok prerez bolnikov s srčno-žilnim tveganjem.
Onychoclasis
ledvična odpoved
Onychoclasis
lomljenje nohtov
onychoclasis,
oniholiza,
Onychorrhexis
onihoreksa
Oocyte retrieval is performed 34-35 hours later.
Oocite odvzamite 34 do 35 ur pozneje.
oot present around mouth, nose and/or oropharynx altered mental status
prisotnost saj okrog ust, nosa in/ali orofarinksa; spremenjeno duševno stanje.
Oother medicines and Insulin Human Winthrop Comb 15
Druga zdravila in Insulin Human Winthrop Comb 15
oozing from operation wound site
izcedek iz rane na mestu operacije;
oozing of blood or fluid from surgical wound
izcejanje krvi ali tekočine iz kirurške rane
OPA-Al-PVC/Al blisters in cartons of 28, 30, 35, 50, 56, 70 or 98 orodispersible tablets per carton.
OPA-aluminij-PVC/ aluminij pretisni omoti v škatlah po 28, 30, 35, 50, 56, 70 ali 98 orodisperzibilnih tablet.
OPA/Alu/PVC Aluminium blisters
OPA/Alu/PVC aluminijasti pretisni omoti
OPA/Alu/PVC – Aluminium blisters.
OPA/Alu/PVC – aluminijasti pretisni omoti.
OPA/alu/PVC-alu blisters in cartons of 28, 28 x 1, 30, 30 x 1, 35, 35 x 1, 50, 50 x 1, 56, 56 x 1, 70,
OPA/aluminij/PVC aluminij pretisni omoti v škatlah po 28, 28 x 1, 30, 30 x 1, 35, 35 x 1, 50, 50 x 1,
OPA/alu/PVC-alu blisters in cartons of 28, 30, 35, 50, 56, 70 or 98 film-coated tablets per carton.
OPA/aluminij/PVC aluminij pretisni omoti v škatlah po 28, 30, 35, 50, 56, 70 ali 98 filmsko obloženih tablet.
OPA/alu/PVC-alu blisters in cartons of 28, 30, 35, 56, 70 and 98 film-coated tablets per carton.
OPA/aluminij/PVC aluminij pretisni omoti v škatlah po 28, 30, 35, 56,70 in 98 filmsko obloženih tablet.
OPA/alu/PVC-alu blisters in cartons of 28, 30, 35, 56, 70 or 98 film-coated tablets per carton.
OPA/aluminij/PVC aluminij pretisni omoti v škatlah po 28, 30, 35, 56, 70 ali 98 filmsko obloženih tablet.
OPA/alu/PVC-alu blisters in cartons of 7, 7 x 1, 28, 28 x 1, 30, 30 x 1, 35, 35 x 1, 50, 50 x 1, 56,
OPA/aluminij/PVC aluminij pretisni omoti v škatlah po 7, 7 x 1, 28, 28 x 1, 30, 30 x 1, 35, 35 x 1, 50,
OPA/Aluminium/PVC–Aluminium blisters.
OPA/aluminijsko/PVC -aluminijski pretisni omoti.
Opadry clear (containing hypromellose, macrogol)
Opadry prozorno (vsebuje hipromelozo in makrogol).
Opadry clear: (Hypromellose, macrogol)
Opadry prozorna: (hipromeloza, makrogol)
Opadry green (containing lactose monohydrate, hypromellose, titanium dioxide (E171), glycerol triacetate, FD&C Blue (E132), iron oxide yellow (E172))
Opadry zeleno (vsebuje monohidrat laktoze, hipromelozo, titanov dioksid (E171), gliceroltriacetat, indigotin (E132) in rumeni železov oksid (E172)),
Opadry II Purple 85F90057 (containing polyvinyl alcohol – part hydrolyzed, titanium dioxide, macrogol/PEG, talc, iron oxide black and iron oxide red).
Opadry II Purple 85F90057, ki vsebuje polivinilalkohol (delno hidroliziran), titanov dioksid, makrogol/PEG, smukec, črni železov oksid in rdeči železov oksid.
Opadry II Purple 85F90057 containing: Polyvinyl alcohol – part hydrolyzed titanium dioxide
Opadry II Purple 85F90057, ki vsebuje: polivinilalkohol (delno hidroliziran) titanov dioksid
Opadry Orange YS-1-13065-A containing: hypromellose
Opadry Orange YS-1-13065-A, ki vsebuje: hipromelozo
Opadry white YS-1-7003: Titanium dioxide (E 171) Hypromellose
Opadry white YS-1-7003: titanov dioksid (E171) hipromeloza
Opalescent pink with resuspendable sediment.
Dodatki: aluminijev hidroksid, saponin Opalescentno roza s sedimentom, ki se resuspendira.
Opalescent pink with resuspendable sediment.
Opalescentno roza s sedimentom, ki se resuspendira.
Opalescent suspension for injection.
Opalescentna suspenzija za injiciranje
opalescent, colourless to slightly yellow.
Nastala raztopina mora biti bistra do rahlo opalescentna, brezbarvna do rumenkasta.
Opaque blue body, imprinted with ‘20 mg’ and an opaque blue cap, imprinted with ‘9544’.
Neprozorno modro telo z vtisnjenim napisom ‘20 mg’ ter neprozoren moder pokrovček z vtisnjeno oznako ‘9544’.
Opaque blue cap and opaque yellow body approximately 21.7 mm, imprinted in white ink with ‘MYLAN’ over ‘DL 60’ on both the cap and the body.
Rumena neprozorna kapsula z modrim neprozornim pokrovčkom, velikosti priližno 21,7 mm in z belim črnilom vtisnjeno oznako ‘MYLAN’ preko 'DL 60', na pokrovčku in telesu kapsule.
Opaque green body, imprinted with ‘60 mg’ and an opaque blue cap, imprinted with ‘9542’.
Neprozorno zeleno telo z vtisnjenim napisom ‘60 mg’ ter neprozoren moder pokrovček z vtisnjeno oznako ‘9542’.
Opaque orange body, imprinted with ’40mg’ and an opaque blue cap, imprinted with ‘9545’.
Neprozorno oranžno telo z vtisnjenim napisom ‘40 mg’ ter neprozoren moder pokrovček z vtisnjeno oznako ‘9545’.
Opaque PVC/Aclar blister with push-through aluminium lidding in pack sizes of 14, 28, 56, 84, 98,
Neprozoren pretisni omot iz PVC/Aclarja z aluminijskim prekritjem, skozi katerega se potisne tableta, v pakiranjih s 14, 28, 56, 84, 98, 168, 196 tabletami s prirejenim sproščanjem, multi pakiranje s
Opaque PVC/Aclar/Aluminium foil blisters.
Motni pretisni omoti iz PVC/aluminijske folije.
Opaque PVC/Aluminium blisters.
Neprosojni PVC/aluminijasti pretisni omoti.
Opaque white body, imprinted with ‘30 mg’ and an opaque blue cap, imprinted with ‘9543’.
Neprozorno belo telo z vtisnjenim napisom ‘30 mg’ ter neprozoren moder pokrovček z vtisnjeno oznako ‘9543’.
Opaque, blue, and white hard capsules, marked with “A1001” in black ink, containing white to pale brown powder.
Neprozorne, modre in bele trde kapsule, ki imajo črno oznako „A1001“ in vsebujejo bel do bledo rjav prašek.
Opaque, off-white frozen dispersion.
Neprosojna, belkasta zamrznjena disperzija
Opaque, white, high density polyethylene (HDPE) plastic, 160 ml bottle containing 120 tablets, fitted with polypropylene (PP) child resistant closure.
Neprozoren, bel, 160 ml vsebnik iz polietilena velike gostote (HDPE), ki vsebuje po 120 tablet, opremljen z za otroke varno polipropilensko zaporko (PP).
Opaque, white, high density polyethylene (HDPE) plastic, 160 ml bottle containing 60 tablets, fitted with polypropylene (PP) child resistant closure.
Neprozoren, bel, 160 ml vsebnik iz polietilena velike gostote (HDPE), ki vsebuje po 60 tablet in je opremljen z za otroke varno polipropilensko (PP) zaporko.
Opatanol
EU/1/02/217/002
OPATANOL 1 mg/mL eye drops, solution
OPATANOL 1 mg/ml kapljice za oko, raztopina
OPATANOL 1 mg/mL eye drops, solution Olopatadine
OPATANOL 1 mg/ml kapljice za oko, raztopina olopatadin
OPATANOL contains Benzalkonium chloride
Zdravilo OPATANOL vsebuje benzalkonijev klorid
OPATANOL contains benzalkonium chloride which may cause eye irritation.
Zdravilo OPATANOL vsebuje benzalkonijev klorid, ki lahko povzroči draženje oči.
OPATANOL has no or negligible influence on the ability to drive and use machines.
Zdravilo OPATANOL nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
OPATANOL is a clear and colourless liquid (a solution) supplied in a pack containing either one 5 ml bottle or three 5 ml plastic bottles with screw caps.
OPATANOL je bistra in brezbarvna tekočina (raztopina), ki je na voljo v pakiranjih s 5 ml kapalnim vsebnikom ali s tremi 5 ml plastičnimi kapalnimi vsebniki z navojno zaporko.
OPATANOL is a medicine for treatment of allergic conditions of the eye.
OPATANOL je zdravilo za zdravljenje alergijskih očesnih bolezni.
OPATANOL is used for the treatment of signs and symptoms of seasonal allergic conjunctivitis.
OPATANOL se uporablja za zdravljenje znakov in simptomov sezonskega alergijskega konjunktivitisa.
OPATANOL may be used in paediatric patients three years of age and older at the same dose as in adults.
Zdravilo OPATANOL se pri pediatričnih bolnikih, starih tri leta in več, lahko uporablja v istem odmerku kot pri odraslih.